TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28731003
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 intravenously.
Study: 28731003
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: Standard therapy with Etoposide and Cisplatin.
Study: 25111959
Drug: Bendamustine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 120 mg/m2
Study: 16645967
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (methotrexate 7.5 mg/week + cyclosporine 2.5 mg/kg/day)
Study: 16645967
Drug: Monotherapy (methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (methotrexate + placebo-cyclosporine)
Study: 16645967
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (methotrexate + intraarticular glucocorticoid)
Study: 16645967
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (methotrexate + cyclosporine)
Study: 8983088
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 4 mg/day
Study: 8983088
Drug: Cortisol (CORT)
Normalized name: Corticool
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cortisol (CORT) 10 mg/h
Study: 1457111
Drug: Atracurium (0.05,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.05, 0.1, or 0.15 mg/kg IV) with desflurane
Study: 1457111
Drug: Atracurium (0.05,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.05, 0.1, or 0.15 mg/kg IV) with isoflurane
Study: 6091501
Drug: Metoclopramide, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide, 10 mg in the morning (Group II)
Study: 6091501
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg (Group III)
Study: 6091501
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg and metoclopramide, 10 mg in the morning (Group IV)
Study: 6091501
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg at bedtime and in the morning (Group V)
Study: 6091501
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg at bedtime and in the morning and metoclopramide, 10 mg in the morning (Group VI)
Study: 6091501
Drug: Ranitidine, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 300 mg in the morning (Group VII)
Study: 6091501
Drug: Ranitidine, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 300 mg and metoclopramide, 10 mg in the morning (Group VIII)
Study: 6091501
Drug: Ranitidine, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 300 mg at bedtime and in the morning (Group IX)
Study: 6091501
Drug: Ranitidine, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 300 mg at bedtime and in the morning and metoclopramide, 10 mg in the morning (Group X)
Study: 27267500
Drug: Enhanced cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced cognitive behavioral therapy (CBT‐E)
Study: 27467700
Drug: Optimized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized treatment as usual (TAU‐O)
Study: 19502285
Drug: Oxytocin 5
Normalized name: oxytocin 5 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin 5 u (first dose)
Study: 19502285
Drug: Oxytocin 5
Normalized name: oxytocin 5 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin 5 u (second dose)
Study: 15172774
Drug: amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amphotericin B plus flucytosine (100 mg/kg daily)
Study: 15172774
Drug: amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amphotericin B (0.7 mg/kg daily)
Study: 15172774
Drug: amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amphotericin B plus fluconazole (400 mg daily)
Study: 15172774
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy with amphotericin B, flucytosine, and fluconazole
Study: 8259900
Drug: Quantitative progressive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quantitative progressive exercise muscle rehabilitation program (QPE) added to physical therapy (PT) program
Study: 21956168
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg daily for 3 months
Study: 18684743
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg subcutaneously every other week for up to 120 weeks
Study: 17250578
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine dentifrice gel (CHX‐DGel, Perio.Aid)
Study: 15710852
Drug: Rasagiline 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1.0 mg/d
Study: 15710852
Drug: Rasagiline 0.5
Normalized name: rasagiline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 0.5 mg/d
Study: 15710852
Drug: Rasagiline 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1.0 mg/d vs Placebo
Study: 15710852
Drug: Rasagiline 0.5
Normalized name: rasagiline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 0.5 mg/d vs Placebo
Study: 12043767
Drug: Anabolic steroids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anabolic steroids, vitamin D and calcium
Study: 7861490
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg, orally 3 times a day for 4 days)
Study: 6791203
Drug: Lentizol (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentizol (sustained-release amitriptyline)
Study: 6791203
Drug: Ordinary amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary amitriptyline tablets
Study: 30670228
Drug: Dual-task aquatic
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-task aquatic exercise program, twice a week for 10 weeks, 40 minutes per session in a heated pool (33°C)
Study: 28507373
Drug: LASER therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LASER therapy
Study: 28713116
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of exercise and LASER therapy
Study: 26137324
Drug: Lithium (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (n = 23, 0.79 ± 0.15 mEq/L)
Study: 26137324
Drug: Valproate (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (n = 13, 79.6 ± 12.4 mg/mL)
Study: 17205445
Drug: E-test antibiotic
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-test antibiotic strips (AB Biodisk) applied directly on respiratory tract samples
Study: 10891925
Drug: m-chlorophenylpiperazine (mCPP)
Normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-chlorophenylpiperazine (mCPP) 0.5 mg/kg
Study: 1364953
Drug: Trans‐scleral panretinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans‐scleral panretinal cryocoagulation in combination with cyclo‐cryocoagulation
Study: 3843217
Drug: Clobazam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (15 to 60 mg per day)
Study: 3843217
Drug: Clobazam (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (dose changes)
Study: 3492260
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b (Intron A) high dose (50 X 10(6) IU/m2 intravenously)
Study: 3492260
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b (Intron A) intermediate dose (30 X 10(6) IU/m2 subcutaneously)
Study: 3492260
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b (Intron A) low dose (1 X 10(6) IU/m2 subcutaneously)
Study: 3492260
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b (Intron A) high dose
Study: 23279371
Drug: Bilateral superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral superficial cervical plexus block with 15 mL of 0.25% bupivacaine (group B)
Study: 23279371
Drug: Bilateral superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral superficial cervical plexus block with 0.25% bupivacaine and 1 μg/kg clonidine (group BC)
Study: 20122367
Drug: Ondansetron 16
Normalized name: ondansetron 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 16 mg per day for 10 weeks
Study: 18004687
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (SB: NaHCO3 300 mg . kg (‐1) body mass)
Study: 18004687
Drug: Placebo (P:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P: CaCO3 200 mg . kg (‐1) body mass)
Study: 11094666
Drug: ropivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.125% with fentanyl 2 micrograms/ml
Study: 8883031
Drug: Antacid, ranitidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid, ranitidine, and misoprostol (prostaglandin E1)
Study: 8883031
Drug: Antacid and
Normalized name: Antacid And Antigas
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid and ranitidine
Study: 8883031
Drug: Antacid, ranitidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid, ranitidine, and bismuth (De Nol)
Study: 1383590
Drug: Mexicord (antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexicord (antiarrhythmic agent)
Study: 23385630
Drug: Pegaptanib (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegaptanib (0.3 mg)
Study: 17164742
Drug: ranolazine 1000
Normalized name: ranolazine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranolazine 1000 mg b.i.d. (n=22)
Study: 3898298
Drug: Thymopentin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (50 mg, intravenous injections, 3 times a week for 3 consecutive weeks)
Study: 29077992
Drug: Exendin‐(9‐39) at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exendin‐(9‐39) at a maximum recommended starting dose of 27 mg kg‐1 day‐1 intravenously
Study: 27003305
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CCK and Metformin
Study: 22287353
Drug: FOLFOX4 as
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4 as conventional neoadjuvant chemotherapy (Group A)
Study: 22287353
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy delivered 5 days after bevacizumab treatment according to NWTV (Group C)
Study: 18519778
Drug: rhIL-18 administered
Normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-18 administered as a 2-h i.v. infusion on 5 consecutive days repeated every 28 days (group A)
Study: 18519778
Drug: rhIL-18 administered
Normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-18 administered as a 2-h i.v. infusion once a week (group B)
Study: 1828543
Drug: Subcutaneous rHuEPO
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rHuEPO (84 ± 9 U/kg body weight/week)
Study: 1828543
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who were hypertensive prior to rHuEPO therapy
Study: 7317896
Drug: Propranolol (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (360 mg/day)
Study: 31859096
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily routine care)
Study: 26189231
Drug: High-dose midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose midazolam (MDZ) alone (G1)
Study: 26189231
Drug: Low-dose MDZ
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MDZ and dexmedetomidine (DEX) (G2)
Study: 26189231
Drug: High-dose MDZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose MDZ and DEX (G3)
Study: 26189231
Drug: Low-dose MDZ
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MDZ and high-dose DEX (G4)
Study: 26189231
Drug: High-dose MDZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose MDZ and low-dose DEX (G5)
Study: 26189231
Drug: High-dose DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DEX alone (G6)
Study: 23737255
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing Lactobacillus reuteri (2 × 10^8 CFU per dose), twice daily for 12 weeks
Study: 19225530
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 or 10 mg)
Study: 17014994
Drug: Saline intraoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline intraoral injection
Study: 11411890
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (read radiographs twice, received no intervention)
Study: 25092108
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine (LC) 1000 mg/d
Study: 21775070
Drug: Capecitabine (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1,200 mg/m(2)/d Mondays through Friday) and Irinotecan (50 mg/m(2) weekly in four doses) with concurrent radiotherapy (50.4 Gy in 1.8‐Gy fractions) (Arm 1)
Study: 21775070
Drug: Capecitabine (1,650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1,650 mg/m(2)/d Monday through Friday) and Oxaliplatin (50 mg/m(2) weekly in five doses) with concurrent radiotherapy (50.4 Gy in 1.8‐Gy fractions) (Arm 2)
Study: 19383889
Drug: 12‐week Better
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12‐week Better Exercise Adherence after Treatment for Cancer intervention
Study: 17616297
Drug: Tirofiban infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban infusion followed by sirolimus-eluting stent (SES)
Study: 15135267
Drug: 1mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg of 17 beta‐estradiol orally combined with 100 mg progesterone
Study: 15135267
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg transdermally combined with 100 mg progesterone
Study: 9133340
Drug: Sugar-coated tablet
Normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sugar-coated tablet formulation (Femavit 1.25)
Study: 9133340
Drug: Oral suspension
Normalized name: Oral Suspension
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral suspension
Study: 8188994
Drug: Gastrolyte (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrolyte (240 mosm/l)
Study: 8188994
Drug: Glucolyte (340
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucolyte (340 mOsm/l)
Study: 3532900
Drug: Ketanserine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserine (80 mg/day for 6 months)
Study: 29609013
Drug: Bimekizumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab (all doses)
Study: 26884472
Drug: Intranasal glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal glucagon (3 mg)
Study: 17650792
Drug: Biliary drainage
Normalized name: PLEURX DRAINAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biliary drainage via endoscope (ENBD) combined with Chinese drug medication (CTG)
Study: 17650792
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment with ENBD alone (RTG)
Study: 15618250
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg twice daily for 3 months)
Study: 15618250
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg for 3 months)
Study: 10465169
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 30 mg once daily for 14 days
Study: 31083704
Drug: AW group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AW group (18% oral carbohydrate solution)
Study: 23528626
Drug: mesalamine (Asacol
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalamine (Asacol 800‐mg tablet) 4.8 g/day
Study: 23528626
Drug: mesalamine (Asacol
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalamine (Asacol 800‐mg tablet) 4.8 g/day after excluding ineligible patients
Study: 19344437
Drug: Valganciclovir (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir (900 mg/day)
Study: 19344437
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (3000 mg/day)
Study: 9743397
Drug: Antihistamines (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamines (1 mg/kg diphenhydramine and 4 mg/kg cimetidine)
Study: 2563688
Drug: Benorylate 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benorylate 4 g
Study: 25733462
Drug: High-protein preload
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein preload (PRO; 29 g)
Study: 25733462
Drug: High-calcium preload
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calcium preload (CAL; 1170 mg)
Study: 11025704
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy for benign prostatic hyperplasia
Study: 1457115
Drug: ORG 9426
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 9426 (all doses)
Study: 6233348
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (n = 24)
Study: 6233348
Drug: Pharmacotherapy (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (n = 24)
Study: 6233348
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus pharmacotherapy (n = 22)
Study: 6233348
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus active placebo (n = 17)
Study: 6233348
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment modalities
Study: 26825365
Drug: Clopacin(®) 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopacin(®) 75 mg
Study: 26825365
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (originator)
Study: 23054063
Drug: Paracetamol 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1,000 mg + Caffeine 130 mg (PCF)
Study: 23054063
Drug: Sumatriptan 50
Normalized name: sumatriptan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 50 mg (SUM)
Study: 18370567
Drug: No HMG-CoA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No HMG-CoA reductase inhibitor (statin) therapy
Study: 16319510
Drug: Gemcitabine (GMC)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (GMC) 1,200 mg/m² on days 1 and 8, Cisplatin (CDDP) 75 mg/m² on day 2, repeated every 21 days
Study: 11752998
Drug: Intrathecal adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal adenosine (2 mg)
Study: 7484027
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg kg‐1
Study: 7484027
Drug: Suxamethonium 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1 mg kg‐1 without prior atracurium or anticholinesterase administration
Study: 2387660
Drug: acetyl-L-carnitine
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetyl-L-carnitine
Study: 6113021
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g sulphasalazine retention enemas
Study: 31936621
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BJ) 140 mL
Study: 27942868
Drug: Experimental Music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Music Therapy Group (EMG)
Study: 23274144
Drug: FDC capsule
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC capsule containing lamivudine/adefovir dipivoxil 100/10 mg
Study: 23274144
Drug: Conventional lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conventional lamivudine 100 mg + adefovir dipivoxil 10 mg tablets
Study: 23274144
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (FDC and conventional tablets)
Study: 2005294
Drug: Home-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based treatment
Study: 26287652
Drug: Hospital-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-based treatment
Study: 29631747
Drug: Otic drops
Normalized name: Otic Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otic drops
Study: 9058223
Drug: Mivacurium chloride
Normalized name: Mivacurium Chloride
DrugBank: Mivacurium (DB01226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mivacurium chloride 0.2 mg/kg
Study: 9058223
Drug: Mivacurium chloride
Normalized name: Mivacurium Chloride
DrugBank: Mivacurium (DB01226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mivacurium chloride (both doses)
Study: 8342319
Drug: Bivalent cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent cold recombinant type A (CRA) vaccines